Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of continuous infusion HRS-9190 for neuromuscular blockade maintenance during general anesthesia
CTR20260718Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS-9190 in None, sponsored by Hengrui Therapeutics. Started Apr 2026; status: completed.
02
Drugs
HRS-9190
Beyond the preview
Go deeper on CTR20260718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260718.